VIP for Lungs & Breathing
A potent bronchodilator and pulmonary vasodilator in the lab — but with a half-life measured in minutes and a clinical-trial record that undercuts the online hype.
How It Works
VIP binds VPAC1 and VPAC2 receptors on airway smooth muscle, raising cyclic AMP and relaxing the airways — a genuinely potent bronchodilator and pulmonary vasodilator in acute dosing (Mathioudakis 2013).
Infused into healthy volunteers, plasma VIP fell with a disappearance half-time of about one minute (Domschke 1978). Any “immediately noticeable” effect fades almost as fast as it appears.
The same dose that dilates airways also lowers blood pressure and causes flushing and a faster heart rate (Domschke 1978) — which is why researchers study inhaled, lung-targeted delivery rather than systemic injection.
Beyond dilation, VIP shifts immune cells toward regulatory T cells; a 4-week inhaled VIP study in sarcoidosis was safe and reduced TNF-α production (Prasse 2010) — an anti-inflammatory signal, not a workout bronchodilator.
What the Data Shows
Key Takeaways
- VIP is a real neuropeptide and a potent bronchodilator and vasodilator via VPAC1 and VPAC2 receptors on airway smooth muscle (Mathioudakis 2013).
- Infused VIP has an extremely short plasma half-life — about one minute in healthy volunteers (Domschke 1978).
- At doses that affect the airways, systemic VIP causes flushing, a faster heart rate, and blood-pressure changes (Domschke 1978).
- Inhaled VIP produced only “modest and short-lived” pulmonary vasodilation in a controlled 20-patient study (Leuchte 2008).
- A 4-week inhaled VIP course was safe and reduced TNF-α production in sarcoidosis, pointing to an anti-inflammatory role (Prasse 2010).
- In the largest trial — 471 patients — IV aviptadil did not improve COVID-19 respiratory-failure outcomes and was stopped for futility (odds ratio 1.11, p=0.54; TESICO 2023).
- Whether self-injected VIP produces any durable, “immediately noticeable” breathing benefit in healthy people — no trial has tested this.
- Whether any bronchodilation outlasts VIP's ~1-minute clearance without inhaled or continuous dosing.
- The long-term safety of repeated VIP dosing outside monitored clinical settings.
- Optimal dose, delivery route, and formulation — stabilized inhaled agonists remain investigational.
- Whether the early open-label pulmonary-hypertension results (Petkov 2003) would survive a modern controlled trial — larger controlled studies have been far more modest.
Frequently Asked Questions
Does VIP work as a bronchodilator?
In the lab, yes — VIP relaxes airway smooth muscle through VPAC1 and VPAC2 receptors and is a potent bronchodilator (Mathioudakis 2013). The practical problem is duration: infused VIP clears from plasma with a half-life of about one minute (Domschke 1978), so any effect is fleeting without inhaled or continuous delivery.
Is VIP 'one of the most immediately noticeable' peptides?
That claim circulates on social media but isn't backed by trials. VIP does cause fast, whole-body effects — flushing, a faster heart rate, and blood-pressure changes (Domschke 1978) — which a user may 'feel,' but those are systemic vasodilation, not a proven, lasting breathing benefit. No controlled study has tested self-injected VIP in healthy people.
What happened in the VIP clinical trials?
Early excitement came from an 8-patient, open-label pulmonary-hypertension study (Petkov 2003). A single-dose inhaled study — 20 patients, one 100-µg dose measured during heart catheterization, with no placebo arm — found only 'modest and short-lived' vasodilation (Leuchte 2008), and the largest trial — 471 patients with COVID-19 respiratory failure — showed no benefit and was stopped for futility (TESICO 2023).
Is VIP the same as aviptadil?
Aviptadil is the synthetic, pharmaceutical form of vasoactive intestinal peptide used in clinical trials for pulmonary hypertension and COVID-19 respiratory failure. When a study says 'aviptadil,' it means VIP.
What is VIP actually being researched for?
The most promising direction is anti-inflammatory, not bronchodilation: inhaled VIP shifted immune cells toward regulatory T cells and lowered TNF-α in a 4-week sarcoidosis study (Prasse 2010). Respiratory uses remain investigational and depend on stabilized, inhaled formulations.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Vasoactive intestinal peptide / aviptadil is an investigational compound; it is not an approved treatment for breathing, athletic, or general wellness use.
Consult a qualified healthcare provider before considering any peptide.